Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PRS042
MIFTS: 42

Prostate Disease

Categories: Endocrine diseases, Nephrological diseases, Reproductive diseases
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Prostate Disease

About this section

MalaCards integrated aliases for Prostate Disease:

Name: Prostate Disease 12 15 17
Prostatic Diseases 44 70
Prostate Diseases 42

Classifications:

MalaCards categories:
Anatomical: Reproductive diseases Nephrological diseases Endocrine diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:47
ICD9CM 34 602.9
MeSH 44 D011469
NCIt 50 C26865
SNOMED-CT 67 30281009
UMLS 70 C0033575
Sources

Summaries for Prostate Disease

About this section
MedlinePlus : 42 The prostate is a gland in men. It helps make semen, the fluid that contains sperm. The prostate surrounds the tube that carries urine away from the bladder and out of the body. A young man's prostate is about the size of a walnut. It slowly grows larger with age. If it gets too large, it can cause problems. This is very common after age 50. The older men get, the more likely they are to have prostate trouble. Some common problems are Prostatitis - inflammation, usually caused by bacteria Enlarged prostate (BPH), or benign prostatic hyperplasia - a common problem in older men which may cause dribbling after urination or a need to go often, especially at night Prostate cancer - a common cancer that responds best to treatment when detected early NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Prostate Disease, also known as prostatic diseases, is related to prostatic hypertrophy and prostatic adenoma, and has symptoms including tremor, angina pectoris and equilibration disorder. An important gene associated with Prostate Disease is PCA3 (Prostate Cancer Associated 3). The drugs Povidone-iodine and Povidone have been mentioned in the context of this disorder. Affiliated tissues include prostate, spinal cord and smooth muscle.

Wikipedia : 73 The prostate is both an accessory gland of the male reproductive system and a muscle driven mechanical... more...

Sources

Related Diseases for Prostate Disease

About this section

Diseases related to Prostate Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 108)
# Related Disease Score Top Affiliating Genes
1 prostatic hypertrophy 31.5 SRD5A1 KLK3 AR
2 prostatic adenoma 31.5 SRD5A1 KLK3 CDKN2B-AS1 AR
3 prostatic hyperplasia, benign 31.5 SRD5A1 PCA3 KLK3 FOLH1 AR
4 nodular prostate 30.5 KLK3 AR
5 gynecomastia 30.4 SRD5A1 KLK3 AR
6 prostate cancer 30.3 TERC SRD5A1 SCHLAP1 PTENP1 PRNCR1 PCGEM1
7 suppression of tumorigenicity 12 30.3 KLK3 FOLH1 AR
8 urethral stricture 30.3 KLK3 FOLH1
9 bladder cancer 30.2 TERC SCHLAP1 PCAT1 MEG3 MALAT1 H19
10 prostate neuroendocrine neoplasm 10.6 KLK3 FOLH1 AR
11 androgenic alopecia 10.6 SRD5A1 KLK3 AR
12 prostate adenoid cystic carcinoma 10.6 KLK3 AR
13 prostate leiomyoma 10.6 KLK3 AR
14 lymph node carcinoma 10.6 KLK3 FOLH1 AR
15 prostate calculus 10.6 KLK3 AR
16 griscelli syndrome, type 3 10.6 SCHLAP1 PCA3 KLK3
17 ovarian epithelial cancer 10.5 PCA3 MEG3 MALAT1 H19
18 bronchiectasis 3 10.5 KLK3 AR
19 thyroid carcinoma 10.5 MALAT1 H19 GAS5 CDKN2B-AS1
20 lymphocele 10.5 KLK3 FOLH1
21 thyroid cancer, nonmedullary, 1 10.5 MEG3 MALAT1 H19
22 prostatic acinar adenocarcinoma 10.5 KLK3 AR
23 glioma 10.5 MEG3 MALAT1 H19 GAS5 CDKN2B-AS1 CBR3-AS1
24 osteogenic sarcoma 10.5 PCAT1 MEG3 MALAT1 H19 GAS5 CDKN2B-AS1
25 penis agenesis 10.5 SRD5A1 AR
26 gallbladder cancer 10.5 MEG3 MALAT1 H19 CDKN2B-AS1
27 androgen insensitivity, partial 10.5 SRD5A1 AR
28 alopecia, androgenetic, 1 10.5 SRD5A1 AR
29 myeloma, multiple 10.5 PCAT1 MEG3 MALAT1 H19 GAS5
30 silver-russell syndrome 1 10.5 MEG3 IGF2-AS H19
31 wilms tumor 1 10.5 TERC MEG3 IGF2-AS H19 AR
32 cervical cancer 10.5 TERC PCAT1 MEG3 MALAT1 H19 GAS5
33 esophageal cancer 10.5 PCAT1 MEG3 MALAT1 H19 GAS5 CDKN2B-AS1
34 renal cell carcinoma, nonpapillary 10.5 SCHLAP1 PTENP1 MALAT1 LINC00963 H19 GAS5
35 prostate stromal sarcoma 10.5 PCA3 KLK3
36 osteoarthritis 10.5 PCGEM1 MEG3 H19 GAS5
37 endometrial cancer 10.5 TERC PTENP1 MEG3 KLK3 H19 GAS5
38 nasopharyngeal carcinoma 10.5 MEG3 MALAT1 H19 GAS5 CDKN2B-AS1
39 kidney cancer 10.5 MEG3 MALAT1 H19 GAS5
40 bladder lateral wall cancer 10.5 KLK3 FOLH1
41 high grade glioma 10.5 TERC PRNCR1 PCGEM1 MEG3 MALAT1 LINC00963
42 glioblastoma 10.5 PCAT1 MEG3 MALAT1 LINC00963 H19 GAS5
43 prostate transitional cell carcinoma 10.5 KLK3 AR
44 squamous cell carcinoma 10.5 PCAT1 MALAT1 H19 CDKN2B-AS1 CBR3-AS1
45 male reproductive organ benign neoplasm 10.5 KLK3 AR
46 gastric cancer 10.5 TERC PTENP1 PRNCR1 PCAT1 MEG3 MALAT1
47 hepatocellular carcinoma 10.4 TERC PTENP1 PCAT1 MEG3 MALAT1 IGF2-AS
48 bladder urothelial carcinoma 10.4 MEG3 MALAT1 GAS5
49 vulva squamous cell carcinoma 10.4 MEG3 MALAT1
50 laryngeal squamous cell carcinoma 10.4 MALAT1 H19 CDKN2B-AS1

Comorbidity relations with Prostate Disease via Phenotypic Disease Network (PDN):


Prostate Cancer Prostatic Hypertrophy

Graphical network of the top 20 diseases related to Prostate Disease:



Diseases related to Prostate Disease
Sources

Symptoms & Phenotypes for Prostate Disease

About this section

UMLS symptoms related to Prostate Disease:


tremor; angina pectoris; equilibration disorder; prostatism
Sources

Drugs & Therapeutics for Prostate Disease

About this section

Drugs for Prostate Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 50)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Povidone-iodine Approved Phase 4 25655-41-8
2
Povidone Approved Phase 4 9003-39-8 131751496
3
Iodine Approved, Investigational Phase 4 7553-56-2 807
4
Alfuzosin Approved, Investigational Phase 4 81403-80-7 2092
5
Cadexomer iodine Experimental Phase 4 94820-09-4
6 Anti-Infective Agents, Local Phase 4
7 Anti-Infective Agents Phase 4
8 Plasma Substitutes Phase 4
9 Blood Substitutes Phase 4
10 Neurotransmitter Agents Phase 4
11 Adrenergic alpha-Antagonists Phase 4
12 Adrenergic alpha-1 Receptor Antagonists Phase 4
13 Adrenergic Antagonists Phase 4
14 Adrenergic Agents Phase 4
15
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
16
Ethanol Approved Phase 1, Phase 2 64-17-5 702
17
nivolumab Approved Phase 1, Phase 2 946414-94-4
18 Androgen Antagonists Phase 1, Phase 2
19 Vaccines Phase 1, Phase 2
20 Tubulin Modulators Phase 2
21 Antimitotic Agents Phase 2
22 Albumin-Bound Paclitaxel Phase 2
23 Imatinib Mesylate Phase 2 220127-57-1 123596
24 Protein Kinase Inhibitors Phase 2
25 Hormones Phase 1, Phase 2
26 Androgens Phase 1, Phase 2
27 Hormone Antagonists Phase 1, Phase 2
28 Immunoglobulins, Intravenous Phase 1, Phase 2
29 Antineoplastic Agents, Immunological Phase 1, Phase 2
30 Antibodies Phase 1, Phase 2
31 Immunoglobulin G Phase 1, Phase 2
32 Immunoglobulins Phase 1, Phase 2
33 Antibodies, Monoclonal Phase 1, Phase 2
34
Lidocaine Approved, Vet_approved Phase 1 137-58-6 3676
35
Ceftriaxone Approved Phase 1 73384-59-5 5479530 5361919
36 Anesthetics Phase 1
37 Antibiotics, Antitubercular Phase 1
38 Anti-Bacterial Agents Phase 1
39 Hops Approved
40
Finasteride Approved 98319-26-7 57363
41
Pentetic acid Approved 67-43-6
42
Edetic Acid Approved, Vet_approved 62-33-9, 60-00-4 6049
43 Anesthetics, Local
44 5-alpha Reductase Inhibitors
45 Estrogens
46 Chelating Agents
47 Anticoagulants
48 Calcium, Dietary
49 Radiopharmaceuticals
50
Calcium Nutraceutical 7440-70-2 271

Interventional clinical trials:

(show all 43)
# Name Status NCT ID Phase Drugs
1 A Prospective Randomized Trial of Povidone-iodine Suppository Before Transrectal Ultrasound Guided Prostate Biopsy Unknown status NCT02245334 Phase 4 Povidone-Iodine
2 ALEX-XL: Alfuzosin XL-Lower Urinary Tract Symptoms Efficacy and Sexuality Study Completed NCT00575913 Phase 4 Alfuzosin
3 A Phase I-II Open Label Clinical Trial, Evaluating the Efficacy and Safety of Administration of the Therapeutic Vaccine PEP-223/CoVaccine HT, to Hormone Treatment naïve, Immunocompetent Subjects With T1-3, N0-1/x, M0 Prostate Cancer, Eligible for Hormone Therapy. Unknown status NCT00895466 Phase 1, Phase 2
4 Phase IIa Dose Escalation Trial of NanoPac® Focal Therapy for Prostate Cancer in Subjects Undergoing Radical Prostatectomy Completed NCT03077659 Phase 2 NanoPac®
5 Evaluation of the Safety and Tolerability of Transurethral Alcohol Injection for the Treatment of BPH (Enlarged Prostate) Completed NCT00037141 Phase 1, Phase 2 dehydrated alcohol
6 An Open-label, Multicenter, Phase II Study to Evaluate the Ability of Glivec® (Imatinib, Formerly Known as STI571) to Produce a Biochemical Response in Patients With Rising PSA Following Radical Prostatectomy Completed NCT01316458 Phase 2 STI571 (Glivec®)
7 Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy in the Management of Gleason Group 5 Prostate Cancer Recruiting NCT03543189 Phase 1, Phase 2 Nivolumab;Androgen Deprivation Therapy
8 High-Resolution, 18F-PSMA PET-MRI for Mapping Prostate Cancer in Patients Considering Focal High-Intensity Focused Ultrasound (HIFU) Therapy Not yet recruiting NCT04461509 Phase 2 18F-PSMA
9 A Phase II Study of Ixabepilone Prior to Surgery for High-risk Localized Prostate Cancer Terminated NCT00672009 Phase 2 Ixabepilone
10 A Phase 1/2 Open-Label Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-506 in Patients With Metastatic Castration-Resistant Prostate Cancer Terminated NCT02606123 Phase 1, Phase 2 EPI-506
11 4-aminopyridine Treatment for Nerve Injury From Radical Retro-Pubic Prostatectomy Withdrawn NCT03658408 Phase 2 4-aminopyridine;placebo
12 Pilot Study to Evaluate In Vivo Plastic Scintillation Detectors for Real-Time Radiation Dosimetry During Prostate Cancer Radiotherapy Completed NCT01307852 Phase 1
13 Soractelite(Tm) Transperineal Laser Ablation for Benign Prostatic Hyperplasia With Bladder Outlet Obstruction Recruiting NCT04760483 Phase 1
14 A Phase 1 Dose Escalation and Expanded Cohort Study of P-PSMA-101 in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Recruiting NCT04249947 Phase 1 Rimiducid
15 Ejaculation Preserving Photoselective Vaporization Versus Plasma Kinetic Vaporization Versus Transurethral Resection Of The Prostate For Management Of Benign Prostatic Enlargement: An Objective Evaluation Through a Prospective Randomized Trial Unknown status NCT03589196
16 Sexuality and Management of Benign Prostatic Hyperplasia With Alfuzosin Completed NCT00941343 Alfuzosin (XATRAL® - SL770499)
17 Configuration of a New Prostate Disease Nomogram Predicting Prostate Biopsy Outcome Correlating Clinical Indicators Among Asian Adult Males With Elevated Prostate Specific Antigen (PSA) Completed NCT01826617
18 Prostatic Artery Embolization for Obstructive Uropathy Due to Prostate Cancer Completed NCT03104907
19 Prostatic Artery Embolization for Benign Prostatic Obstruction Completed NCT03099421
20 Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment . Geriatric Oncology Protocol in Aquitaine Country. Completed NCT00210249
21 Prospective Evaluation of the Intraoperative Use of Translumenal Flexible Endoscopes During Combined Flexible and Laparoscopic Foregut and Urologic Surgery Completed NCT00484783
22 A Prospective Randomized Study Whether Low-energy Extracorporeal Shockwave Therapy (LI-ESWT) Can Increase Erectile Function in Patients After Radical Prostatectomy Completed NCT03192917
23 Intratesticular Hormone Levels in Healthy Young Men Completed NCT00756561
24 Randomized, Evaluator-blind, Controlled Trial to Evaluate the Efficacy and Safety of Prostatic Arterial Embolization Versus a Sham Procedure for Benign Prostatic Hyperplasia With Severe LUTS Not Adequately Controlled With Alpha-blockers Completed NCT02074644
25 Validation of a Semiquantitative Screening Assay for PSA Completed NCT00853710
26 Feasibility and Safety of Transurethral HIFU in Various Prostate Diseases; Particularly Prostate Cancer Recruiting NCT03350529
27 Hypnosis Mask: a New Approach to Management of Pain in Medical Imaging Recruiting NCT03711643
28 MR/TRUS Fusion Guided Prostate Biopsy- An Improved Way To Detect And Quantify Prostate Cancer Recruiting NCT04026763
29 MR/TRUS Fusion Guided Prostate Biopsy - An Improved Way to Detect and Quantify Prostate Cancer Recruiting NCT04599218
30 A Study to Evaluate the Safety and Efficacy of Focal US Guided Cryo-ablation Using DynaCAD / UroNAV Preplanning / Guidance of Locally Confined Low to Intermediate Risk Prostate Cancer Recruiting NCT04656678
31 MRI for Assessment of Hypoxia-Induced Prostate Cancer Aggressiveness Recruiting NCT01464216
32 Evaluation of Diagnostic Accuracy of [68Ga]Ga-PSMA-11 PET/CT in Primary Staging of Intermediate and High Risk Prostatic Cancer in Men Newly Diagnosed Recruiting NCT04462926
33 5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy Recruiting NCT04288427 Finasteride
34 Culturally Adapted Cognitive Behavioral Stress and Self-Management (C-CBSM) Intervention for Prostate Cancer Recruiting NCT03344757
35 Biobank for African American Prostate Cancer Research in Florida Active, not recruiting NCT03232411
36 Molecular Studies and Clinical Correlations in Human Prostatic Disease Active, not recruiting NCT00578240
37 Prospective Cohort Study With Collection of Clinical Data, Serum and Plasma of Patients With Prostate Disease Active, not recruiting NCT04024475
38 68Ga PSMA-11 in Patients With Intermediate to High-risk Prostate Cancer Before Prostatectomy or With Biochemical Recurrence of Prostate Cancer. Available NCT04452136 68GA PSMA-HBED-CC
39 Cryoablation: An Observational Study of Hemi-Gland Cryoablation Outcomes for Prostate Cancer at University of California at Los Angeles (UCLA) Enrolling by invitation NCT03503643
40 Evaluation of the in Vivo Biodistribution and Radiation Dosimetry of 68Ga-HTK03149 for Use as a Diagnostic Radiopharmaceutical Not yet recruiting NCT04831307
41 A Questionnaire Study by Elevated Prostate Specific Antigen (PSA): Do Men Where Subsequent Assessment Shows Prostate Cancer, Higher Levels of Neuroticism and Stress Compared to Those Who do Not Get the Diagnosis? Terminated NCT02031029
42 Effect of Laser Settings on Postoperative Voiding Symptoms in Patients Undergoing Holmium Laser Enucleation of the Prostate: A Randomized Prospective Trial Withdrawn NCT04699552
43 ConfirmMDx Assay is Multiparametric MRI (mpMRI) PIRADS Scored Lesions After a Negative MR/US Fusion Biopsy Withdrawn NCT03597386

Search NIH Clinical Center for Prostate Disease

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Mannitol hexanitrate

Cochrane evidence based reviews: prostatic diseases

Sources

Genetic Tests for Prostate Disease

About this section
Sources

Anatomical Context for Prostate Disease

About this section

MalaCards organs/tissues related to Prostate Disease:

40
Prostate, Spinal Cord, Smooth Muscle, Bone, Endothelial, Pituitary, Lymph Node
Sources

Publications for Prostate Disease

About this section

Articles related to Prostate Disease:

(show top 50) (show all 1555)
# Title Authors PMID Year
1
Transrectal Ultrasound Guided Prostatic Biopsy and its Complications: A Descriptive Cross-sectional Study. 42
32335639 2020
2
Selenium Supplementation and Prostate Health in a New Zealand Cohort. 42
31861307 2019
3
Burkholderia et abcès de prostate. 42
31884988 2019
4
Estrogen receptor-related receptor alpha mediates up-regulation of aromatase expression by prostaglandin E2 in prostate stromal cells. 61 54
20351196 2010
5
Differential percentage of serum prostate-specific antigen subforms suggests a new way to improve prostate cancer diagnosis. 61 54
19670261 2010
6
Psychological distress and prostate specific antigen levels in men with and without prostate cancer. 54 61
19486654 2009
7
Biomarkers for prostate cancer. 61 54
19507229 2009
8
The natural compound atraric acid is an antagonist of the human androgen receptor inhibiting cellular invasiveness and prostate cancer cell growth. 61 54
18627423 2009
9
Risk of developing prostate cancer in the future: overview of prognostic biomarkers. 54 61
19375623 2009
10
Glycomic characterization of prostate-specific antigen and prostatic acid phosphatase in prostate cancer and benign disease seminal plasma fluids. 61 54
19128049 2009
11
5alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications. 61 54
19030020 2009
12
[CXCR4 combined with P504S or P63 in differential diagnosis of benign and malignant prostatic diseases]. 61 54
19157222 2008
13
Nonhuman primates as models for studies of prostate specific antigen and prostatic diseases. 61 54
18668524 2008
14
5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression. 61 54
18320593 2008
15
[Differentiation of prostate cancer from benign prostatic disease by total prostate specific antigen dynamic profiles after transrectal prostate biopsy]. 61 54
18686378 2008
16
Androgen receptor modulation: lessons learned from beyond the prostate. 61 54
17881894 2007
17
A preliminary study of the baboon prostate pathophysiology. 61 54
17639509 2007
18
Significance of prostate specific antigen in prostate cancer patients and in non cancerous prostatic disease patients. 54 61
17571482 2007
19
Serum prostate-specific antigen levels in Middle Eastern men with subclinical prostatitis. 54 61
17159365 2007
20
Age-specific reference ranges for prostate specific antigen-total and free in patients with prostatitis symptoms and patients at risk. 61 54
17318358 2006
21
Prostate specific antigen levels in young adulthood predict prostate cancer risk: results from a cohort of Black and White Americans. 61 54
16093978 2005
22
Pharmacogenetic analysis of human steroid 5 alpha reductase type II: comparison of finasteride and dutasteride. 54 61
15956333 2005
23
Inhibition of dendropoiesis by tumor derived and purified prostate specific antigen. 54 61
14532846 2003
24
Relationship between Prostatic Specific Antigen (PSA) and volume of the prostate in the Benign Prostatic Hyperplasia in the elderly. 54 61
12962896 2003
25
Elevated serum progastrin-releasing peptide (31-98) level is a predictor of short response duration after hormonal therapy in metastatic prostate cancer. 61 54
12858359 2003
26
Value of prostate specific antigen alpha1-antichymotrypsin complex for the detection of prostate cancer in patients with a PSA level of 4.1-10.0 ng/mL: comparison with PSA-related parameters. 61 54
11903683 2001
27
The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease. 61 54
11720279 2001
28
[Urinary problems and prostate-specific antigen in a Norwegian normal population]. 61 54
11301608 2001
29
Diagnostic accuracy of percent free prostate-specific antigen in prostatic pathology and its usefulness in monitoring prostatic cancer patients. 54 61
11741128 2001
30
Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer. 54 61
11326656 2000
31
Effect of two years of growth hormone and insulin-like growth factor-I suppression on prostate diseases in acromegalic patients. 61 54
11061535 2000
32
Polyarteritis nodosa mimicking prostatic cancer. 54 61
11036851 2000
33
[Screening for prostatic diseases in one-day total health check-up by using prostate specific antigen, international prostate symptom score and QOL index]. 61 54
11107529 2000
34
Change in the ratio of free-to-total prostate-specific antigen during progression of advanced prostate cancer. 54 61
10750886 2000
35
Prostate-specific membrane antigen levels in sera from healthy men and patients with benign prostate hyperplasia or prostate cancer. 61 54
10632336 1999
36
Ratio of gamma-seminoprotein to prostate-specific antigen for the detection of prostate cancer: its discrimination power could be influenced by the assay methods of PSA and/or gamma-seminoprotein. 61 54
10510889 1999
37
An algorithm combining age, total prostate-specific antigen (PSA), and percent free PSA to predict prostate cancer: results on 4298 cases. 54 61
9730460 1998
38
Prostate-specific antigen (protein and mRNA) analysis in the differential diagnosis and staging of prostate cancer. 54 61
9352130 1997
39
PSA divergence. A new parameter for the accurate longitudinal assessment of prostatic disease. 61 54
8638528 1996
40
[Influence of age on serum prostate specific antigen concentration]. 61 54
9594181 1996
41
Prostate-specific antigen and its complexes with alpha 1-antichymotrypsin in the plasma of patients with prostatic disease. 54 61
8977078 1996
42
Prostate-specific antigen (PSA) and cancer-associated serum antigen (CASA) in distinguishing benign and malignant prostate disease. 61 54
8750649 1995
43
Molecular mass and carbohydrate structure of prostate specific antigen: studies for establishment of an international PSA standard. 54 61
7479385 1995
44
Prostate-specific antigen density: the role in benign prostate hyperplasia, prostate intraepithelial neoplasm, organ-confined prostate carcinoma and advanced prostate carcinoma. 61 54
8725043 1995
45
Prostate-specific antigen and human glandular kallikrein: two kallikreins of the human prostate. 61 54
7521173 1994
46
[Variability of values of prostate-specific antigen determined with 6 methods]. 54 61
7514278 1994
47
Influence of digital examination, cystoscopy, transrectal ultrasonography and needle biopsy on the concentration of prostate-specific antigen. 61 54
7531895 1994
48
[Examination of serum prostate specific antigen (PSA) in the mass screening for prostatic diseases]. 61 54
7685140 1993
49
[Significance of prostatic acid phosphatase, gamma-seminoprotein and prostatic specific antigen in the urine. First report: the measurement of PAP, gamma-Sm and PA in the urine of patients with prostatic diseases]. 54 61
1721770 1991
50
[A mass screening of the prostatic diseases and serum prostate specific antigen]. 61 54
1720276 1991
Sources

Variations for Prostate Disease

About this section
Sources

Expression for Prostate Disease

About this section
Search GEO for disease gene expression data for Prostate Disease.
Sources

Pathways for Prostate Disease

About this section
Sources

GO Terms for Prostate Disease

About this section

Biological processes related to Prostate Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of systemic arterial blood pressure GO:0003073 8.96 KLK3 AR
2 cellular response to testosterone stimulus GO:0071394 8.62 SRD5A1 AR
Sources

Sources for Prostate Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....